DGAP-News: Medios AG: Successful completion of the acquisition of the NewCo Pharma Group - Significant expansion of the market position in the area of manufacturing

Press Release

Medios AG: Successful completion of the acquisition of the NewCo Pharma Group - Significant expansion of the market position in the area of manufacturing

Berlin, January 11, 2022 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, has successfully completed the acquisition of the specialized pharmaceutical manufacturer NewCo Pharma GmbH, Mannheim. All closing conditions have been met.

The merger with the NewCo Pharma Group will enable Medios to significantly strengthen in particular its Patient-specific Therapies segment and thus also to significantly and sustainably increase the profit margins of the entire Medios Group. Together with NewCo Pharma, Medios aims to exceed the 1.5-billion-euro revenue mark in 2022 and increase its EBITDA pre¹ margin to well over 3%.

Matthias Gaertner, CEO of Medios AG: "We are pleased with the fast and successful completion of the acquisition of the NewCo Pharma Group. As a result, our attractive business with patient-specific therapies for the treatment of rare and chronic diseases will triple. Together with the NewCo Pharma Group, we are laying the foundation for even more profitable sustainable growth. The expanded network will enable us to position the Medios Group even better as a close partner to local specialized pharmacies throughout Germany. Patients will also benefit from this."

NewCo Pharma Group is a national network with five regional compounding facilities and wholesale with a regional focus on northern, western and southern Germany. They focus on the manufacture of patient-specific infusion solutions on behalf of specialized pharmacies. Through the merger with NewCo Pharma GmbH, Medios' partner network will grow from currently 550 to then around 600 specialized pharmacies.

¹ EBITDA is defined as net earnings before interest, income taxes, depreciation and amortization. EBITDA pre is     
   adjusted for extraordinary expenses for stock options, M&A activities and amortization of the customer base.

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact
Claudia Nickolaus
Head of Investor and Public Relations
& ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin | Germany
P +49 30 232 566 800
[email protected]
www.medios.ag

Nikolaus Hammerschmidt
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg | Germany
P +49 40 609 186 18
[email protected]
www.kirchhoff.de

Disclaimer

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.